Results 31 to 40 of about 983 (198)

Patients with obstructive sleep apnea in Germany. [PDF]

Sleep Breath
Solriamfetol is approved for use in the European Union to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). SURWEY characterized real-world evidence regarding physician initiation and titration strategies and patient
Winter Y, Mayer G, Benes H, Burghaus L, Floam S, Parks GS, Kallweit U.   +6 more
europepmc   +2 more sources

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. [PDF]

CNS Drugs
Excessive daytime sleepiness (EDS) is a prominent symptom of obstructive sleep apnea (OSA), negatively affecting patients’ quality of life. The objective of this study was to assess the efficacy and safety of solriamfetol in patients with OSA with EDS ...
Cheng H, Deng L, Meng Z, Zhang W, Chen T, Chen R, Tang S, Lv Y, Su X, Liu Z, Zhang X, Wang X, Mao H, Zhang N, Yu H, Pan J, Xie Y, Tang J, Yin S, Wang Z, Tong M, Zhan S, Wang C, Wang B, Zhang W, Mi W, Lu L.   +26 more
europepmc   +2 more sources

Drug-Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. [PDF]

Arthritis Rheumatol
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Hlavaty A, Dari L, Cracowski JL, Roustit M, Khouri C.   +4 more
europepmc   +2 more sources

P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol [PDF]

SLEEP Advances, 2021
Abstract Introduction Solriamfetol (Sunosi) is a dopamine/norepinephrine reuptake inhibitor approved (EU/US) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75–150 mg/day) or obstructive sleep apnoea (OSA) (37.5–150 mg/day).
Thorpy, M, Hyman, D, Parks, G, Chen, A, Foley, C, Ito, D, Singh, H   +6 more
openaire   +1 more source

Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial. [PDF]

Hum Psychopharmacol, 2023
Abstract Objective To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on‐the‐road driving performance in participants with narcolepsy. Methods In this randomised, double‐blind, placebo‐controlled, crossover study, driving performance during a 1 h on‐road driving test was assessed at 2 and 6 h post‐dose ...
Vinckenbosch F, Lammers GJ, Overeem S, Chen D, Wang G, Carter LP, Zhou K, Ramaekers JG, Vermeeren A.   +8 more
europepmc   +2 more sources

Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy [PDF]

Sleep Medicine, 2022
Paula, Susan Redline
exaly   +2 more sources

Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario [PDF]

Advances in Therapy, 2022
Haramandeep Singh, Danielle L Hyman, Gregory S Parks   +2 more
exaly   +2 more sources

Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort [PDF]

, 2022
Introduction: Narcolepsy is a chronic and rare hypersomnia of central origin characterized by excessive daytime sleepiness and a complex array of symptoms as well as by several medical comorbidities.
Agostoni E. C., Blanchard N., Bonanni E., Brunetti V., Centonze D., Cicolin A., Della Marca G., Ferini-Strambi L., Ferri R., Figorilli M., Gigli G. L., Izzi F., Lecomte I., Liguori C., Liguori R., Lodi R., Mutti C., Nobili L., Parrino L., Pedrazzi G., Pizza F., Placidi F., Plazzi G., Proserpio P., Puligheddu M., Romigi A., Sacco T., Savarese M. A., Terzaghi M.   +28 more
core   +5 more sources

Trends and variation in issuance of high-cost narcolepsy drugs by NHS England organisations and regions from 2019 to 2022. [PDF]

J Sleep Res
Summary Clinicians and people with narcolepsy report varied access to higher‐cost narcolepsy treatments in England associated with variations in national and local commissioning. There are no publicly available data quantifying use of these drugs to support policy decisions. We therefore aimed to describe national, regional and local prescribing trends
van Someren F, Wiedemann M, Warren-Gash C, Sykorova M, Mistry H, Miller MA, Leschziner G, Nolte E, Belot A, Smith IE, Quinnell T, Eriksson SH, Strongman H.   +12 more
europepmc   +2 more sources

Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. [PDF]

, 2022
Study objectivesThis post hoc analysis characterized the weekly incidence and overall duration of common early-onset, treatment-emergent adverse events (TEAEs) during solriamfetol treatment.MethodsParticipants (obstructive sleep apnea [OSA], n = 474 ...
Bujanover, Shay, Dauvilliers, Yves, Gotfried, Mark, Malhotra, Atul, Rosenberg, Russell, Scheckner, Brian, Schweitzer, Paula K, Thorpy, Michael J, Zammit, Gary   +8 more
core   +2 more sources